 |
 |

Safety of Immediate Transverse Rectus Abdominis Myocutaneous Breast Reconstruction for Patients With Locally Advanced Disease
Robert D. Foster, MD;
Scott L. Hansen, MD;
Laura J. Esserman, MD, MBA;
E. Shelley Hwang, MD;
Cheryl Ewing, MD;
Karen Lane, MD;
James P. Anthony, MD
Arch Surg. 2005;140:196-200.
Hypothesis Immediate transverse rectus abdominis myocutaneous breast reconstruction combined with postoperative radiation therapy after mastectomy is safe and effective.
Design Retrospective case series.
Setting University-based teaching hospital.
Patients From January 1, 1996, through December 31, 2003, 252 patients underwent mastectomy and immediate transverse rectus abdominis myocutaneous flap reconstruction. Of those, 35 patients received postoperative radiation therapy (stage I, n = 1; II, n = 17; III, n = 15; IV, n = 2). Age range was 29 to 72 years (mean, 49.5 years). Follow-up was 1 to 8 years (mean, 48 months).
Main Outcome Measures Flap loss, fat necrosis, flap volume loss, adjuvant treatment delay, and need for additional surgery.
Results The rate of flap survival was 100%. Median operative time was 5.5 hours. Average hospital stay was 5.2 days. Fat necrosis occurred in 3 patients, with volume loss requiring additional surgery in 2 patients (6%). Postoperative adjuvant therapy was not significantly delayed (median interval, 32 days). With a median follow-up of 48 months, local recurrence was present in only 1 patient (3%), who underwent successful local salvage, and distant metastasis occurred in 4 patients (11%).
Conclusions Immediate transverse rectus abdominis myocutaneous breast reconstruction followed by radiation therapy is safe, with minimal morbidity and no significant change in tissue volume. Complications tend to be minor, not delaying adjuvant therapy. Immediate breast reconstruction should be considered after mastectomy, despite the need for postoperative radiation therapy.
Author Affiliations: Division of Plastic and Reconstructive Surgery (Drs Foster, Hansen, and Anthony) and Department of Surgery (Drs Foster, Hansen, Esserman, Hwang, Ewing, Lane, and Anthony), University of California, San Francisco.
Correspondence: Robert D. Foster, MD, Division of Plastic and Reconstructive Surgery, University of California, San Francisco, 350 Parnassus Ave, Suite 509, San Francisco, CA 94143-0932 (fosterr{at}surgery.ucsf.edu).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
This Month in Archives of Surgery
Arch Surg. 2005;140(2):115.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Prospective Multicenter Comparison of Models to Predict Four or More Involved Axillary Lymph Nodes in Patients With Breast Cancer With One to Three Metastatic Sentinel Lymph Nodes
Werkoff et al.
JCO 2009;27:5707-5712.
ABSTRACT
| FULL TEXT
Statement of the Science Concerning Locoregional Treatments After Preoperative Chemotherapy for Breast Cancer: A National Cancer Institute Conference
Buchholz et al.
JCO 2008;26:791-797.
ABSTRACT
| FULL TEXT
|